Pseudomonas aeruginosa in bronchiectasis: unmasking population diversity and antimicrobial resistance in the Australian context

ABSTRACT Background: Pseudomonas aeruginosa infections in bronchiectasis airways result in poorer lung function, advanced lung lobe involvement, worsened life quality, and higher hospitalisation rates. Despite high prevalence, little is known about P. aeruginosa population genomics, antimicrobial resistance (AMR) rates, persistence, and transmission dynamics in Australians with bronchiectasis. Methods: P. aeruginosa (n=137) isolated between 2009 and 2025 from 59 Australians with bronchiectasis underwent antimicrobial susceptibility testing against 11 antipseudomonal drugs, whole-genome sequencing, comparative genomics, and in silico AMR determinant identification. Data were integrated with 4,575 publicly available bronchiectasis-derived P. aeruginosa genomes to determine global phylogenomic and AMR determinant patterns. Results: High AMR rates were identified in the Australian isolates, with 75.9% resistant to at least one antimicrobial, 19.7% multidrug-resistant, and 9.5% extremely drug-resistant. AMR rates were highest (64.2%) for ciprofloxacin and cefepime (44.5%), and lowest for piperacillin/tazobactam (8.8%) and colistin (0.7%). Phylogenomics uncovered several instances of within-host evolution, hypermutation, persistence, and multi-lineage infections. Of the fifty-seven identified multilocus sequence types (STs), seven (12.3%) were novel, five were high-risk international clones (ST274 [6.6%], ST395 [0.7%], ST244 [0.7%], ST277 [0.7%], ST298 [0.7%]) and three were common global clones (ST253 [5.1%], ST155 [3.6%], ST260 [0.7%]). No high-risk AMR-conferring mobile genetic elements were seen, although numerous chromosomal AMR determinants were identified. AMR determinant prevalence was consistent with the global dataset, with no evidence of geographic clustering. Conclusions: Our study provides critical insights into P. aeruginosa diversity in Australians with bronchiectasis. High AMR rates and chronic colonisation highlight the need to improve diagnostics, antimicrobial stewardship measures, and infection control practices in this neglected clinical cohort.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-15
DOI
https://doi.org/10.64898/2026.11.13.26367559
Primary Topic
Antibiotic Resistance in Bacteria
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Pseudomonas aeruginosa in bronchiectasis: unmasking population diversity and antimicrobial resistance in the Australian context

Lucy D. Burr, Louise McIntosh, Kellie R. Strickland, Erin P. Price et al.
medRxiv
Antibiotic Resistance in Bacteria
preprint

Pseudomonas aeruginosa in bronchiectasis: unmasking population diversity and antimicrobial resistance in the Australian context

Lucy D. Burr, Louise McIntosh, Kellie R. Strickland, Erin P. Price, Derek S. Sarovich, Julia J. Bashford, Timothy Baird, Andrew Burke, Emily M. Dunn, Joshua Brock, Ieuan Evans, Miriana L. Littlejohn, Jacob Christensen, Jasmine L Davies
preprint en

Abstract

ABSTRACT Background: Pseudomonas aeruginosa infections in bronchiectasis airways result in poorer lung function, advanced lung lobe involvement, worsened life quality, and higher hospitalisation rates. Despite high prevalence, little is known about P. aeruginosa population genomics, antimicrobial resistance (AMR) rates, persistence, and transmission dynamics in Australians with bronchiectasis. Methods: P. aeruginosa (n=137) isolated between 2009 and 2025 from 59 Australians with bronchiectasis underwent antimicrobial susceptibility testing against 11 antipseudomonal drugs, whole-genome sequencing, comparative genomics, and in silico AMR determinant identification. Data were integrated with 4,575 publicly available bronchiectasis-derived P. aeruginosa genomes to determine global phylogenomic and AMR determinant patterns. Results: High AMR rates were identified in the Australian isolates, with 75.9% resistant to at least one antimicrobial, 19.7% multidrug-resistant, and 9.5% extremely drug-resistant. AMR rates were highest (64.2%) for ciprofloxacin and cefepime (44.5%), and lowest for piperacillin/tazobactam (8.8%) and colistin (0.7%). Phylogenomics uncovered several instances of within-host evolution, hypermutation, persistence, and multi-lineage infections. Of the fifty-seven identified multilocus sequence types (STs), seven (12.3%) were novel, five were high-risk international clones (ST274 [6.6%], ST395 [0.7%], ST244 [0.7%], ST277 [0.7%], ST298 [0.7%]) and three were common global clones (ST253 [5.1%], ST155 [3.6%], ST260 [0.7%]). No high-risk AMR-conferring mobile genetic elements were seen, although numerous chromosomal AMR determinants were identified. AMR determinant prevalence was consistent with the global dataset, with no evidence of geographic clustering. Conclusions: Our study provides critical insights into P. aeruginosa diversity in Australians with bronchiectasis. High AMR rates and chronic colonisation highlight the need to improve diagnostics, antimicrobial stewardship measures, and infection control practices in this neglected clinical cohort.

medRxiv
University of the Sunshine Coast (AU), Mater Research (AU), Sunshine Coast University Hospital (AU), Prince Charles Hospital (AU), Prince Charles Hospital (GB)
Antibiotic Resistance in Bacteria
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon